Accepting new patients (614) 430-8022 7965 N High St, Suite 205
Optimed Immunology
Patient Portal Schedule Consultation

What is HyQvia?

HyQvia is a unique facilitated subcutaneous immunoglobulin product from Takeda. By combining 10% IgG with recombinant hyaluronidase, it allows monthly large-volume subcutaneous administration — combining the convenience of monthly dosing typical of IVIG with the stable absorption and lower side-effect profile of subcutaneous administration.

What it treats

HyQvia is FDA-approved for the following indications:

  • Primary humoral immunodeficiency
  • CIDP maintenance

How it is administered

HyQvia is administered subcutaneously every three to four weeks. The hyaluronidase component temporarily expands the subcutaneous tissue space to accommodate larger volumes than would otherwise be possible. Most patients can self-administer at home after initial training.

Patient assistance & support

The manufacturer offers a patient support program — Takeda OnePath — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.takedapatientsupport.com.

Coordination at Optimed Immunology

Treatment with HyQvia is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. This is a subcutaneous self-administered medication. After prior authorization, the prescription is sent to a specialty pharmacy that ships the medication directly to the patient. A manufacturer-sponsored nurse or office-based training visit is typically arranged for the first dose so patients are confident with self-administration before continuing at home.

Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.hyqvia.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether HyQvia is appropriate for your situation.

Medically reviewed

Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine

Last reviewed: November 2025 · Sources: FDA prescribing information · manufacturer label · AAAAI · ACAAI · relevant clinical guidelines

This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.

Have questions about HyQvia?

Treatment selection is a shared decision. Schedule a consultation with Dr. McNeil to discuss whether HyQvia is appropriate for you.